(0.09%) 5 474.25 points
(0.10%) 39 152 points
(0.41%) 17 790 points
(-0.21%) $80.66
(-3.66%) $2.66
(-0.77%) $2 312.90
(0.20%) $28.93
(3.49%) $1 020.80
(0.27%) $0.936
(0.68%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases...
Stats | |
---|---|
今日成交量 | 297 124 |
平均成交量 | 1.19M |
市值 | 330.10M |
EPS | $-0.130 ( Q2 | 2024-05-09 ) |
下一个收益日期 | ( $-0.130 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-7.80 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00700 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-14 | Donhauser Peter D.o. | Buy | 2 835 | Common Stock |
2024-05-15 | Thomas Steffen | Buy | 5 000 | Common Stock |
2024-03-28 | Missling Christopher U | Buy | 73 380 | Common Stock |
2024-03-28 | Missling Christopher U | Sell | 73 380 | Common Stock |
2024-03-28 | Missling Christopher U | Sell | 73 380 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
2.49 |
Last 100 transactions |
Buy: 6 192 856 | Sell: 2 192 392 |
音量 相关性
Anavex Life Sciences Corp 相关性 - 货币/商品
Anavex Life Sciences Corp 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-0.600 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-0.600 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-0.620 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.540 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Anavex Life Sciences Corp
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。